Have a personal or library account? Click to login
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors Cover

Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors

Radiology and Oncology
Volume 58 (2024): Issue 2 (June 2024)
By: Maria Ingenerf,  Christoph Auernhammer,  Roberto Lorbeer,  Michael Winkelmann,  Shiwa Mansournia,  Nabeel Mansour,  Nina Hesse,  Kathrin Heinrich,  Jens Ricke,  Frank Berger and  Christine Schmid-Tannwald  
Open Access
|Apr 2024

Figures & Tables

FIGURE 1.

Flow-chart of including process of patients.CAP/TEM = capecitabine and temozolomide; DWI = diffusion-weighted imaging
Flow-chart of including process of patients.CAP/TEM = capecitabine and temozolomide; DWI = diffusion-weighted imaging

FIGURE 2.

A 72-year-old man with liver metastasis of pancreatic NET classified as responder with a PFS of 38 months. The baseline axial contrast-enhanced T1- weighted image (hepatobiliary phase) (A) shows hypointense lesions (arrows) in segment 8 and exophytic in segment 1. The metastases show (B) restricted diffusion (arrows) with high signal on axial DW-MR image b = 800 s/mm2 and dark signal (arrows) on ADC map (C). After initiation of CAPTEM, the metastases (arrows) exhibited a decrease in size (D) On the axial DW-MR image b = 800 s/mm2, the metastasis (arrow) (E) demonstrated less hyperintense signal to liver and predominantly hyperintense signal (circle) on the ADC map (F) indicating less restricted diffusion compared to the preinterventional image.ADC = apparent diffusion coefficient; CAPTEM = capecitabine and temozolomide; DW-MR = diffusion-weighted magnetic resonance; NET = neuroendocrine tumor; PFS = progression-free survival; PR =partial remission; TARE = transarterial radioembolization
A 72-year-old man with liver metastasis of pancreatic NET classified as responder with a PFS of 38 months. The baseline axial contrast-enhanced T1- weighted image (hepatobiliary phase) (A) shows hypointense lesions (arrows) in segment 8 and exophytic in segment 1. The metastases show (B) restricted diffusion (arrows) with high signal on axial DW-MR image b = 800 s/mm2 and dark signal (arrows) on ADC map (C). After initiation of CAPTEM, the metastases (arrows) exhibited a decrease in size (D) On the axial DW-MR image b = 800 s/mm2, the metastasis (arrow) (E) demonstrated less hyperintense signal to liver and predominantly hyperintense signal (circle) on the ADC map (F) indicating less restricted diffusion compared to the preinterventional image.ADC = apparent diffusion coefficient; CAPTEM = capecitabine and temozolomide; DW-MR = diffusion-weighted magnetic resonance; NET = neuroendocrine tumor; PFS = progression-free survival; PR =partial remission; TARE = transarterial radioembolization

FIGURE 3.

A 56-year-old man with liver metastasis of pancreatic NET classified as nonresponder with a PFS of 3 months. The baseline axial contrast-enhanced T1- weighted image (hepatobiliary phase) (A) shows a hypointense lesion (arrow) in segment 4A. The metastasis shows a strong artrerial enhancement (B) and restricted diffusion (arrow) with high signal on axial DW-MR image b = 800 s/mm2 (C) and dark signal (arrow) on ADC map (D). After 3 months under CAPTEM, the metastasis (arrow) (E) exhibited an increase in size; however, it shows less arterial enhancement (F). On the axial DW-MR image b = 800 s/mm2, the metastasis (arrow) demonstrated hyperintense signal to liver and increasing hypointense signal on the ADC map indicating increasing restricted diffusion compared to the baseline image ADC, apparent diffusion coefficient.ADC = apparent diffusion coefficient; CAPTEM = capecitabine and temozolomide; DW-MR = diffusion-weighted magnetic resonance; NET = neuroendocrine tumor; PFS = progression-free survival
A 56-year-old man with liver metastasis of pancreatic NET classified as nonresponder with a PFS of 3 months. The baseline axial contrast-enhanced T1- weighted image (hepatobiliary phase) (A) shows a hypointense lesion (arrow) in segment 4A. The metastasis shows a strong artrerial enhancement (B) and restricted diffusion (arrow) with high signal on axial DW-MR image b = 800 s/mm2 (C) and dark signal (arrow) on ADC map (D). After 3 months under CAPTEM, the metastasis (arrow) (E) exhibited an increase in size; however, it shows less arterial enhancement (F). On the axial DW-MR image b = 800 s/mm2, the metastasis (arrow) demonstrated hyperintense signal to liver and increasing hypointense signal on the ADC map indicating increasing restricted diffusion compared to the baseline image ADC, apparent diffusion coefficient.ADC = apparent diffusion coefficient; CAPTEM = capecitabine and temozolomide; DW-MR = diffusion-weighted magnetic resonance; NET = neuroendocrine tumor; PFS = progression-free survival

FIGURE 4.

(A) Survival analysis for ∆ size of NELM with a cut-off of ≤ 0% for responder. This cut-off revealed a slightly longer median PFS time of 12.2 vs. 3.6 month (p = 0.062). (B) The median cut-off for ∆ ADCmean/ADCmean liver showed a significantly longer median PFS time of 15.3 compared to 4.1 month (p = 0.024). Both the combination of ∆ size of NELM > 0% and ∆ ADCmin < − 2.9% and the combination of ∆ size of NELM > 0% and ∆ CgA > 12.6% could differentiate patients with a longer median PFS time. Median PFS of the group with ∆ size of NELM > 0% and ∆ ADCmin < −2.9% was 3.6 m compared to 12 months (p = 0.021) in the group not fulfilling these criteria or a maximum of one criterion. Median PFS of the group with ∆ size of NELM > 0% and ∆ CgA > 12.6% was 3.6 m compared to 11.3 months (p = 0.072) in the group not fulfilling these criteria or a maximum of one criterium.ADC = apparent diffusion coefficient; CgA = chromogranin A; NELM = neuroendocrine liver metastasis; PFS = progression-free survival
(A) Survival analysis for ∆ size of NELM with a cut-off of ≤ 0% for responder. This cut-off revealed a slightly longer median PFS time of 12.2 vs. 3.6 month (p = 0.062). (B) The median cut-off for ∆ ADCmean/ADCmean liver showed a significantly longer median PFS time of 15.3 compared to 4.1 month (p = 0.024). Both the combination of ∆ size of NELM > 0% and ∆ ADCmin < − 2.9% and the combination of ∆ size of NELM > 0% and ∆ CgA > 12.6% could differentiate patients with a longer median PFS time. Median PFS of the group with ∆ size of NELM > 0% and ∆ ADCmin < −2.9% was 3.6 m compared to 12 months (p = 0.021) in the group not fulfilling these criteria or a maximum of one criterion. Median PFS of the group with ∆ size of NELM > 0% and ∆ CgA > 12.6% was 3.6 m compared to 11.3 months (p = 0.072) in the group not fulfilling these criteria or a maximum of one criterium.ADC = apparent diffusion coefficient; CgA = chromogranin A; NELM = neuroendocrine liver metastasis; PFS = progression-free survival

ROC analysis of the previously selected imaging and clinical parameters

AUCCut-off (Median)Sensitivity (%)Specificity (%)Youden-Index
Ki-67%0.72> 1569590.28
Hepatic tumor burden0.73< 1084720.56
∆ CgA0.73> 12.667640.31
∆Size NELM0.71> 069650.34
∆ Size PNET-> −2.7100500.50
∆ ADCmin0.71< −2.965630.28
∆ ADCmean/ADCmean liver0.76< 6.976750.51
∆ Size NELM+ ∆ CgA0.79> 0/> 12.678600.38
∆ Size NELM+ ∆ ADCmin0.70> 0/< −2.988600.48
∆ Size NELM+ ∆ ADCmean/ ADCmean liver0.77> 0/< 6.978580.36

Patients characteristics

Baseline N = 44Follow-Up N = 33
Age (years)60.4 (50.5; 70.2)
Males33 (75.0%)
Time initial diagnosis – therapy start685 (199; 1230)
Clinical parameter
  Hepatic tumor burden (%)10 (5 ;40)
  CgA (ng/ml)610 (119; 2093)647 (261; 2357)
  Bilirubin (mg/dl)0.6 (0.4; 0.8)0.7 (0.6; 0.9)
  Grading
    11 (2.4%)
    232 (76.2%)
    36 (14.3%)
    NEC = 43 (7.1%)
Ki-67 primary tumor (%)15 (8;20)
Localization primary tumor
    Pancreas37 (84.1%)
    Lung7 (15.9%)
MRI parameter
NELM
    Size (mm)28 (19;36)24.5 (18;38.5)
    T1 non-contrast/T1 liver0.62 (0.53;0.68)0.68 (0.56;0.75)
    T2/T2 liver1.63 (1.16;2.07)1.66 (1.21;2.17)
    ADCmin448.5 (242.5;628.5)549 (341;848)
    ADCmean903 (708.5;1069.5)969 (764;1250)
    ADCmin/ADCmin liver0.80 (0.60;0.93)0.85 (0.51;1.32)
    ADCmean/ADCmean liver0.82 (0.74;0.96)0.99 (0.65;1.32)
    % arterial vascularization42.5 (15;80)22.5 (5;74.5)**
PNET
    Size (mm)43 (32;70)43 (29.5;52)
    T1 non-contrast /T1 pancreas0.63 (0.59;0.76)0.68 (0.61;0.84)
    T2/T2 pancreas1.38 (0.85;1.67)1.08 (0.83;1.34)
    ADCmin604.5 (237;648)628 (499.5;758.5)
    ADCmean985 (810;1150)1042.5 (939;1167)
    ADCmin/ADCmin pancreas0.69 (0.41;1.11)0.73 (0.58;0.85)
    ADCmean/ADCmean pancreas1.01 (0.78;1.19)0.89 (0.72;0.97)
    % arterial vascularization15 (10;80)7 (5;45)

Differences in change of clinical and imaging tumor parameters between responder and non-responder

Change between baseline and follow-up (%)Non-responder (< 6 months PFS) N = 17Responder (≥ 6 months PFS) N = 16p-value
Clinical parameter
  CgA61.2 (−8.3;251.9)−1.5 (−69.3;19)0.036
  Bilirubin0 (−20;40)8.3 (−15.3;133.3)0.312
MRI parameter
NELM
  Size (mm)20 (−4.7;50)−8.0 (−20.1;2.2)0.038
  T1 non-contrast/T1 liver5.4 (−3.8;32.6)−6.8 (−13.6;11.2)0.078
  T2/T2 liver1.6 (−9.2;24.1)−5.7 (−26.2;32.8)0.589
  ADCmin−22.8 (−41.1;40.2)49.7 (−6.7;146.4)0.037
  ADCmean−3.5 (−18.4;14.1)11.7 (−3.4;75.4)0.056
  ADCmin/ADCmin liver−32.3 (−46.2;70.8)47.5 (12.7;251.7)0.113
  ADCmean/ADCmean liver−16.3 (−30.6;6.9)30.0 (6.9;90.4)0.011
  % arterial vascularization−16.7 (−75; −5.9)−16.7 (−50.0;11.8)0.298
PNET
  Size (mm)2.3 (−5.4;20)−55 (−60; −17.8)0.013
  T1 non-contrast /T1 pancreas7.4 (−3.8;36.7)−5 (−19.7;1.9)0.116
  T2/T2 pancreas−16.6 (−22;1.2)−36.1 (−40.3; −10.1)0.229
  ADCmin14.4 (−13.7;260.8)18.7 (−33.2;48.9)0.782
  ADCmean8.3 (−4.5;29.3)4.0 (−26.3;4.6)0.405
  ADCmin/ADCmin pancreas−3.6 (−29;76.6)53 (−18.4;80.9)0.518
  ADCmean/ADCmean pancreas−23.2 (−35.5;4.5)−5.7 (−14.3;0.2)0.518
  % arterial vascularization−50 (−80;0)−50 (−80;0)0.851

Differences in baseline clinical and imaging tumor parameters between responder and non-responder

Non-responder (< 6 months PFS) N = 23Responder (≥ 6 months PFS) N = 21p-value
Age57.8 (44.1;71.1)61.7 (55.8;68.8)0.953
Males16 (69.6%)17 (81.0%)0.494
Time ID – Therapy start (d)851 (426;1552)396 (153;1004)0.115
Clinical parameter
  Hepatic tumor burden (%)5 (5;20)20 (10;40)0.007
  CgA592 (116;2031)616 (156.5;2745)0.706
  Bilirubin0.6 (0.4;0.8)0.6 (0.3;0.9)0.859
  Grading 0.234
    10 (0%)1 (5%)
    215 (68.2%)17 (85%)
    34 (18.2%)2 (10%)
    NEC = 43 (13.6%)0 (0%)
  Ki-67 primary tumor (%)16.5 (10;30)10.0 (5;15)0.013
  Localization primary tumor 0.232
    Pancreas21 (91.3%)16 (76.2%)
    Lung2 (8.7%)5 (23.8%)
MRI parameter
NELM
    Size (mm)25.5 (17;33.5)29.8 (21.8;37.5)0.348
    T1 non-contrast/T1 liver0.60 (0.53;0.68)0.64 (0.54;0.74)0.263
    T2/T2 liver1.62 (1.2;2.07)1.69 (1.12;2.06)0.903
    ADCmin506 (228;639)424 (243;606)0.827
    ADCmean852.5 (674;1059)911 (790.5;1082.5)0.495
    ADCmin/ADCmin liver0.80 (0.63;0.93)0.74 (0.51;1.03)0.846
    ADCmean/ADCmean liver0.82 (0.68;0.93)0.86 (0.78;1.02)0.342
    % arterial vascularization45 (15;85)36.3 (15;72.5)0.494
PNET
    Size (mm)38 (30;44)75.5 (65;85.5)0.024
    T1 non-contrast /T1 pancreas0.60 (0.58;0.71)0.71 (0.63;0.8)0.258
    T2/T2 pancreas1.38 (0.84;1.67)1.38 (1.11;1.5)0.777
    ADCmin604.5 (237;648)527 (316.5;698)1.000
    ADCmean893 (789;1055)1084 (996.5;1256)0.157
    ADCmin/ADCmin pancreas0.79 (0.41;1.18)0.63 (0.44;0.8)0.480
    ADCmean/ADCmean pancreas1.09 (0.66;1.31)0.97 (0.96;1.1)0.888
    % arterial vascularization10 (5;70)65 (30;85)0.130
DOI: https://doi.org/10.2478/raon-2024-0024 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 196 - 205
Submitted on: Dec 8, 2023
|
Accepted on: Feb 20, 2024
|
Published on: Apr 14, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
neuroendocrine tumors,
liver metastases,
CAPTEM therapy,
clinical parameters,
MR imaging,
treatment response
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2024 Maria Ingenerf, Christoph Auernhammer, Roberto Lorbeer, Michael Winkelmann, Shiwa Mansournia, Nabeel Mansour, Nina Hesse, Kathrin Heinrich, Jens Ricke, Frank Berger, Christine Schmid-Tannwald, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 58 (2024): Issue 2 (June 2024)Next article